Analyst firms · Morgan Stanley · BDX

Morgan Stanley BDX price target and rating history

Becton Dickinson and Company (BDX) · Health Care

Morgan Stanley rates Becton Dickinson and Company (BDX) Overweight with a $295 price target, as of its latest action on May 30, 2023. It has published 3 rating actions on BDX since January 2022, including 0 upgrades and 0 downgrades. Across 6 firms with a BDX price target in the last 12 months, the median target is $191.

Current rating
Overweight
Price target
$295
Median target, all firms
$191
Actions on BDX
3

Morgan Stanley price target on BDX

$310$303$2952023202420252026
Morgan Stanley price target on BDX, each point a stated target, January 2022 to May 2023.

Every Morgan Stanley rating on BDX

How other firms rate BDX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Wells FargoOverweight$242Nov 6, 2026
Wolfe ResearchOutperformOct 20, 2026
UBSBuy$19Jul 28, 2026
Evercore ISIOutperform$180May 4, 2026
Goldman SachsNeutral$167Apr 10, 2026
BarclaysOverweight$202Feb 10, 2026
CitigroupBuy$233Feb 3, 2026

Questions about Morgan Stanley and BDX

What is Morgan Stanley's price target for BDX?
Morgan Stanley's latest stated price target for Becton Dickinson and Company (BDX) is $295, from its action on May 30, 2023.
What is Morgan Stanley's rating on BDX?
Morgan Stanley rates BDX Overweight, a bullish rating, as of May 30, 2023.
When did Morgan Stanley last change its view on BDX?
On May 30, 2023, Morgan Stanley resumes coverage at Overweight, price target $295.
How does Morgan Stanley's BDX target compare with other analysts?
Across 6 firms with a BDX price target in the last 12 months, the median target is $191.

More BDX rating histories

All Morgan Stanley ratingsBDX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.